Shares of argenx SE (ARGX) are up more than 8% Monday morning.
On Friday, the FDA had approved argenx's VYVGARTô for the treatment of adults patients with generalized myasthenia gravis.
Generalized myasthenia gravis is a rare and chronic neuromuscular disease characterized by debilitating and potentially life-threatening muscle weakness.
ARGX is at $337.02 currently. It has traded in the range of $248.21- $382.15 in the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.